US2022041675A1PendingUtilityA1
Variant type iii interferons and synthekines
Assignee: UNIV LELAND STANFORD JUNIORPriority: Sep 30, 2016Filed: Oct 27, 2021Published: Feb 10, 2022
Est. expirySep 30, 2036(~10.2 yrs left)· nominal 20-yr term from priority
A61P 31/20C07K 14/555A61P 35/00C07K 14/57A61K 38/00A61K 31/7088
62
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Compositions and methods are provided relating to Type III interferons.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A polynucleotide encoding an IFNλ variant polypeptide comprising one or more amino acid substitutions that increase affinity to a cognate receptor relative to the wild-type protein, wherein the one or more amino acid substitutions comprise a substitution in at least one or both of Q26 and E84, where numbering is relative to SEQ ID NO:3.
2 . A cell that produces an IFNλ variant polypeptide comprising one or more amino acid substitutions that increase affinity to a cognate receptor relative to the wild-type protein, wherein the one or more amino acid substitutions comprise a substitution in at least one or both of Q26 and E84, where numbering is relative to SEQ ID NO:3.Join the waitlist — get patent alerts
Track US2022041675A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.